[go: up one dir, main page]

WO2006093793A8 - Compositions comprising actinidia and methods of use thereof - Google Patents

Compositions comprising actinidia and methods of use thereof

Info

Publication number
WO2006093793A8
WO2006093793A8 PCT/US2006/006437 US2006006437W WO2006093793A8 WO 2006093793 A8 WO2006093793 A8 WO 2006093793A8 US 2006006437 W US2006006437 W US 2006006437W WO 2006093793 A8 WO2006093793 A8 WO 2006093793A8
Authority
WO
WIPO (PCT)
Prior art keywords
actinidia
compositions
methods
disclosed
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/006437
Other languages
French (fr)
Other versions
WO2006093793A2 (en
WO2006093793A3 (en
Inventor
Hyang Jeon
Julianne Lindemann
George E Stagnitti
Robert H Driver
Mark A Braman
Nancy E Fogg-Johnson
Sunyoung Kim
Eun-Jin Park
Bongcheol Kim
Mirim Jin
Hyung-Jin Jung
Sung-Seup Shin
Jin-Hwan Oh
Hwa-Jun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pangenomics Co Ltd
Original Assignee
Pangenomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangenomics Co Ltd filed Critical Pangenomics Co Ltd
Priority to AU2006218875A priority Critical patent/AU2006218875B2/en
Priority to MX2007010408A priority patent/MX2007010408A/en
Priority to EP06735914A priority patent/EP1858535A4/en
Priority to BRPI0608042-1A priority patent/BRPI0608042A2/en
Priority to JP2007557161A priority patent/JP2008531584A/en
Publication of WO2006093793A2 publication Critical patent/WO2006093793A2/en
Publication of WO2006093793A3 publication Critical patent/WO2006093793A3/en
Anticipated expiration legal-status Critical
Priority to US12/015,193 priority patent/US20080175888A1/en
Publication of WO2006093793A8 publication Critical patent/WO2006093793A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed are novel preparations of Actinidia, and particularly species of hardy kiwifruit, as well as compositions comprising the same. Also disclosed is the use of these preparations of Actinidia to prevent and/or treat a variety of diseases in which regulation of the immune response is effective, including both allergic and non-allergic inflammatory disease, viral infection, and cancer. Methods related to making and using these compositions are also described.
PCT/US2006/006437 2005-02-25 2006-02-24 Compositions comprising actinidia and methods of use thereof Ceased WO2006093793A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2006218875A AU2006218875B2 (en) 2005-02-25 2006-02-24 Compositions comprising Actinidia and methods of use thereof
MX2007010408A MX2007010408A (en) 2005-02-25 2006-02-24 COMPOSITIONS THAT INCLUDE ACTINIDIA AND ITS METHODS OF USE.
EP06735914A EP1858535A4 (en) 2005-02-25 2006-02-24 ACTINIDIA COMPOSITIONS AND METHODS OF USE
BRPI0608042-1A BRPI0608042A2 (en) 2005-02-25 2006-02-24 compositions comprising actinidia and methods for the use of this
JP2007557161A JP2008531584A (en) 2005-02-25 2006-02-24 Composition comprising the genus Matabia and method of using the same
US12/015,193 US20080175888A1 (en) 2005-02-25 2008-01-16 Combination Therapy Comprising Actinidia and Steroids and Uses Thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65683905P 2005-02-25 2005-02-25
US65683805P 2005-02-25 2005-02-25
US60/656,838 2005-02-25
US60/656,839 2005-02-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11817216 A-371-Of-International 2006-02-24
US12/015,193 Continuation-In-Part US20080175888A1 (en) 2005-02-25 2008-01-16 Combination Therapy Comprising Actinidia and Steroids and Uses Thereof

Publications (3)

Publication Number Publication Date
WO2006093793A2 WO2006093793A2 (en) 2006-09-08
WO2006093793A3 WO2006093793A3 (en) 2006-12-07
WO2006093793A8 true WO2006093793A8 (en) 2008-03-27

Family

ID=36941647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/006437 Ceased WO2006093793A2 (en) 2005-02-25 2006-02-24 Compositions comprising actinidia and methods of use thereof

Country Status (8)

Country Link
EP (1) EP1858535A4 (en)
JP (1) JP2008531584A (en)
AU (1) AU2006218875B2 (en)
BR (1) BRPI0608042A2 (en)
MX (1) MX2007010408A (en)
RU (1) RU2423139C2 (en)
TW (1) TWI385007B (en)
WO (1) WO2006093793A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080175888A1 (en) * 2005-02-25 2008-07-24 Julie Lindemann Combination Therapy Comprising Actinidia and Steroids and Uses Thereof
DE102006055210A1 (en) * 2006-11-21 2008-05-29 Ionescu, John G., Dr. Dietary food with increased free radical binding effect
KR101141182B1 (en) 2009-05-12 2012-05-02 재단법인 제주테크노파크 Composition for Anti-inflammation
US9352008B2 (en) 2009-08-12 2016-05-31 Melaleuca, Inc. Dietary supplements and methods for treating pain and inflammation
JP4750202B2 (en) * 2009-10-16 2011-08-17 株式会社 藍匠 Method for producing health supplements using Sarnashi
BR112012016054A2 (en) * 2009-12-29 2015-09-01 Nestec Sa Nutritional compositions comprising fruit flakes including docosahexaenoic acid
JP5688233B2 (en) * 2010-04-23 2015-03-25 ポーラ化成工業株式会社 TARC production inhibitor
JP6179840B2 (en) * 2011-11-30 2017-08-16 国立大学法人 岡山大学 Highly polar organic solvent extract from Sarnashi and its utilization
JP6242669B2 (en) * 2013-11-27 2017-12-06 日本メナード化粧品株式会社 Hyaluronic acid production promoter containing a sarnashi extract
CN105410588B (en) * 2015-11-06 2018-05-08 四川兴食尚科技有限公司 A kind of Kiwi berry effervescent tablet and its preparation process
EP3797297A1 (en) * 2018-05-22 2021-03-31 N.V. Nutricia Biomarkers for improving nutrion for infants at risk

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242814A (en) * 1989-10-10 1993-09-07 Eli Lilly And Company Polyether antibiotic
EP0879056B1 (en) * 1996-01-23 2002-05-02 ICN Pharmaceuticals, Inc. Modulation of th1/th2 cytokine expression by ribavirin in activated t-lymphocytes
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
DE19758090B4 (en) * 1997-12-18 2008-10-16 Maria Endres Composition and its use in cosmetics and medicine
JP2002302458A (en) * 2000-12-26 2002-10-18 Takeda Chem Ind Ltd Combined medicine
EP1263926B1 (en) * 2001-03-29 2006-05-17 Council of Scientific and Industrial Research Process for the preparation of herbal wines from himalayan berries
US6811796B2 (en) * 2002-04-22 2004-11-02 Matsuura Yakugyo Co., Ltd. Preventive or therapeutic agent for pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof
AU2003237987A1 (en) * 2002-06-07 2003-12-22 Ann De Wees Allen Novel sweetener compositions and methods of use
KR100615389B1 (en) * 2002-08-23 2006-08-25 (주)헬릭서 Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease

Also Published As

Publication number Publication date
WO2006093793A2 (en) 2006-09-08
AU2006218875A1 (en) 2006-09-08
MX2007010408A (en) 2008-03-25
RU2423139C2 (en) 2011-07-10
TWI385007B (en) 2013-02-11
JP2008531584A (en) 2008-08-14
TW200716226A (en) 2007-05-01
BRPI0608042A2 (en) 2009-11-03
AU2006218875B2 (en) 2012-08-09
WO2006093793A3 (en) 2006-12-07
EP1858535A4 (en) 2012-05-02
EP1858535A2 (en) 2007-11-28
RU2007135365A (en) 2009-03-27

Similar Documents

Publication Publication Date Title
EP2329835B8 (en) Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease
WO2007054279A8 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2005097175A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2005081687A3 (en) Human hinge core mimetibodies, compositions, methods and uses
WO2006122160A3 (en) Compositions of bakuchiol and methods of making the same
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
NO20016159D0 (en) Serine proteinases from fish and their pharmaceutical and cosmetic uses
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
PL1881823T3 (en) COMPOSITIONS AND METHODS OF EYE DISEASES TREATMENT
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008030511A3 (en) Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004091572A3 (en) Cochleate compositions directed against expression of proteins
WO2006093793A8 (en) Compositions comprising actinidia and methods of use thereof
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2004067567A3 (en) Anti-dengue virus antibodies, compositions, methods and uses
WO2010052575A3 (en) Ngna compositions and methods of use
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
WO2005034857A3 (en) Methods and compositions comprising diamines as new anti-tubercular therapeutics
WO2006130426A3 (en) Modulators of ccr-5 activity
WO2009012785A3 (en) Complexes of an emulgator and a fatty acid
WO2006109301A3 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680013923.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010408

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007557161

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 561749

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006218875

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006735914

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 7367/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007135365

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006218875

Country of ref document: AU

Date of ref document: 20060224

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0608042

Country of ref document: BR

Kind code of ref document: A2